LQDA - Liquidia Technologies

-

$undefined

N/A

(N/A)

Liquidia Technologies NasdaqCM:LQDA Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Location: 419 Davis Drive, Morrisville, NC, 27560, United States | Website: https://www.liquidia.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.592B

Cash

169.8M

Avg Qtr Burn

-24.81M

Short % of Float

20.38%

Insider Ownership

13.48%

Institutional Own.

65.03%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
YUTREPIA (Treprostinil) (LIQ861) Details
Rare diseases, Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease

Approved

Update

YUTREPIA (Treprostinil) (LIQ861) Details
Rare diseases, Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension, Lung disease

Susp. Mover™

PDUFA

Approval decision

Liposomal Treprostinil Inhalation Suspension (L606) Details
Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension

Phase 3

Data readout

LIQ865 Details
Post-surgical pain

Failed

Discontinued